Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 7, 2004, Pages 2538-2543

  Uriarte, Silvia M ^a   Molestina, Robert E ^a,d   Miller, Richard D ^a   Bernabo, Jorge ^b   Farinati, Alicia ^c   Eiguchi, Kumiko ^c   Ramirez, Julio A ^a   Summersgill, James T ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSIDAD DEL SALVADOR   (Argentina)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHEMOKINE; GATIFLOXACIN; INTERLEUKIN 8; LEVOFLOXACIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MOXIFLOXACIN; POLYCARBONATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MIGRATION; CELL STIMULATION; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CYTOKINE RELEASE; DILUTION; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MICROSCOPY; MONOCYTE; NEUTROPHIL; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CELL MOVEMENT; CHEMOKINES; CHLAMYDIA; ENDOTHELIAL CELLS; FLUOROQUINOLONES; HUMANS; MONOCYTES; NEUTROPHILS; OFLOXACIN; PHAGOCYTES; PNEUMONIA, BACTERIAL; QUINOLINES; STIMULATION, CHEMICAL; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 3042573039     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.7.2538-2543.2004     Document Type: Article

References (48)

1. Akamatsu, H., Y. Niwa, H. Sasaki, Y. Matoba, Y. Asada, and T. Horio. 1996. Effect of pyridone carboxylic acid antimicrobials on the generation of reactive oxygen species in vitro. J. Int. Med. Res. 24:345-351.
2. Appelbaum, P. C., and P. A. Hunter. 2000. The fluoroquinolone antibacterials: past, present and future perspectives. Int. J. Antimicrob. Agents 16:5-15.
3. Azuma, Y., M. Shinohara, N. Murakawa, M. Endo, and K. Ohura. 1999. Possible interaction between new quinolones and immune functions in macrophages. Gen. Pharmacol. 32:609-614.
4. Boman, J., and M. R. Hammershlag. 2002. Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin. Microbiol. Rev. 15:1-20.
5. Corti, R., V. Fuster, and J. J. Badimon. 2003. Pathogenic concepts of acute coronary syndromes. JACC 41(Suppl. S):7S-14S.
6. Dalhoff, A., and I. Shalit. 2003. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 6:359-371.
7. Fantoni, M., E. Tamburrini, F. Pallavicini, A. Antinori, and P. Nervo. 1988. Influence of ofloxacin and pefloxacin on human lymphocyte immunoglobulin secretion and on polymorphonuclear leucocyte superoxide anion production. J. Antimicrob. Chemother. 22:193-196.
8. Fryer, R. H., M. L. Woods, and G. M. Rodgers. 1994. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J. Investig. Med. 45:168-174.
9. Gaydos, C. A., J. T. Summersgill, N. N. Sahney, J. A. Ramirez, and T. C. Quinn. 1996. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect. Immun. 64:1614-1620.
10. Godzik, K. L., E. R. O'Brien, S.-K. Wang, and C.-C. Kuo. 1995. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J. Clin. Microbiol. 33:2411-2414.
11. Gollapudi, S. V. S., R. H. Prabhala, and H. Thadepalli. 1986. Effect of ciprofloxacin on mitogen-stimulated lymphocyte proliferation. Antimicrob. Agents Chemother. 29:337-338.
12. Gootz, T. D., J. F. Barrett, and J. A. Sutcliffe. 1990. Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems. Antimicrob. Agents Chemother. 34:8-12.
13. Hahn, D. L., R. W. Dodge, and R. Golubjatnikov. 1991. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult onset asthma. JAMA 266:225-230.
14. Haslett, C., L. A. Guthrie, M. M. Kopaniak, J. Johnston, and P. M. Henson. 1985. Modulation of multiple neutrophl functions by preparative methods of trace concentrations of bacterial lipopolysaccharide. Am. J. Pathol. 119:101-110.
15. Hennig, B., D. M. Shasby, A. B. Fulton, and A. A. Spector. 1984. Exposure to free fatty acids increases the transfer of albumin across cultured endothelial monolayers. Arteriosclerosis 4:489-497.
16. Iion, Y., M. Toriyama, K. Natori, and A. You. 1992. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann. Otol. Rhinol. Laryngol. 101:16-20.
17. Ishiguro, M., H. Koga, S. Kohno, T. Hayashi, K. Yamaguchi, and M. Hirota. 1989. Penetration of macrolides into human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 24:719-729.
18. Jimenez-Valera, M., A. Sampedro, E. Moreno, and A. Ruiz-Bravo. 1995. Modification of immune response in mice by ciprofloxacin. Antimicrob. Agents Chemother. 39:150-154.
19. Kaukoranta-Tolvanen, S. S., K. Laitinen, P. Saikku, and M. Leinonen. 1994. Chlamydia pneumoniae multiplies in human endothelial cells in vitro. Microb. Pathog. 16:313-319.
20. Khan, A. A., T. R. Slifer, and J. S. Remington. 1998. Effect of trovafloxacin on production of cytokines by human monocytes. Antimicrob. Agents Chemother. 42:1713-1717.
21. Koch, A. E., S. L. Kunkel, W. H. Pearce, et al. 1993. Enhanced production of the chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysms. Am. J. Pathol. 142:1423-1431.
22. Korzeniowski, O. M. 1989. Effects of antibiotics on the mammalian immune system. Infect. Dis. Clin. N. Am. 3:469-478.
23. Labro, M.-T. 2000. Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin. Microb. Rev. 13:615-650.
24. Linnanmäki, E., M. Leinonen, K. Mattila, M. S. Nieminen, V. Valtonen, and P. Saikku. 1993. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 87:1130-1134.
25. Matera, G., M. C. Berlinghieri, F. Foti, G. S. Barreca, and A. Foca. 1996. Effect of RO 23-9424, cefotaxime and fleroxacin on functions of human polymorphonuclear cells and cytokine production by human monocytes. J. Antimicrob. Chemother. 38:799-807.
26. Melnick, S. L., E. Shahar, A. R. Folsom, J. T. Grayston, P. D. Sorlie, S.-P. Wang, and M. Szklo. 1993. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am. J. Med. 95:499-504.
27. Molestina, R. E., D. Dean, R. D. Miller, J. A. Ramirez, and J. T. Summersgill. 1998. Characterization of a strain of Chlamydia pneumoniae isolated from a coronary atheroma by analysis of the omp1 gene and biological activity in human endothelial cells. Infect. Immun. 66:1370-1376.
28. Molestina, R. E., R. D. Miller, J. A. Ramirez, and J. T. Summersgill. 1999. Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes. Infect. Immun. 67:1323-1330.
29. Molestina, R. E., R. D. Miller, A. B. Lentsch, J. A. Ramirez, and J. T. Summersgill. 2000. Requirement for NF-κB in transcriptional activation of monocyte chemotactic protein 1 by Chlamydia pneumoniae in human endothelial cells. Infect. Immun. 68:4282-4288.
30. Morikawa, K., F. Oseko, S. Morikawa, and K. Iwamoto. 1994. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob. Agents Chemother. 38:2643-2647.
31. Morikawa, K., H. Watabe, M. Araake, and S. Morikawa. 1996. Modulatory effects of antibiotics on cytokine production by human monocytes in vitro. Antimicrob. Agents Chemother. 40:1366-1370.
32. Nagai, H., H. Shishido, R. Yoneda, E. Yamaguchi, A. Tamura, and A. Kurashima. 1991. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 58:145-149.
33. O'Connor, C. M., M. W. Dunne, M. A. Pfeffer, J. B. Muhlestein, L. Yao, S. Gupta, R. J. Benner, M. R. Fisher, and T. D. Cook. 2003. Azithromycin for the secondary prevention of coronary heart disease events. The WIZARD study: a randomized controlled trial. JAMA 290:1459-1466.
34. Puolakkainen, M., C.-C. Kuo, A. Shor, S.-P. Wang, J. T. Grayston, and L. A. Campbell. 1993. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J. Clin. Microbiol. 31:2212-2214.
35. Ramirez, J. A., S. Ahkee, J. T. Summersgill, B. L. Ganzel, L. L. Ogden, T. C. Quinn, C. A. Gaydos, L. L. Bobo, M. R. Hammerschlag, P. M. Roblin, W. LeBar, J. T. Grayston, C. C. Kuo, L. A. Campbell, D. L. Patton, D. Dean, and J. Schachter. 1996. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann. Intern. Med. 125:979-982.
36. Riesbeck, K., and A. Forsgren. 1994. Limited effects of temafloxacin compared to ciprofloxacin on T-lymphocyte function. Antimicrob. Agents Chemother. 38:879-882.
37. Riesbeck, K., and A. Forsgren. 1994. Increased interleukin 2 transcription in murine lymphocytes by ciprofloxacin. Immunopharmacology 27:155-164.
38. Riesbeck, K. 2002. Immunomodulating activity of quinolones: review. J. Chemother. 1:3-12.
39. Roblin, P. M., W. Dumornay, and M. R. Hammerschlag. 1992. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J. Clin. Microbiol. 30:1968-1971.
40. Roche, Y., M. A. Gougerot-Pocidalo, M. Fay, D. Etienne, N. Forest, and J. J. Pocidalo. 1987. Comparative effects of quinolones on human mononuclear leucocyte functions. J. Antimicrob. Chemother. 19:781-790.
41. Roche, Y., M. Fay, and M.-A. Gougerot-Pocidalo. 1987. Effects of quinolones on interleukin 1 production in vitro by human monocytes. Immunopharmacology 13:99-109.
42. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801-809.
43. Saikku, P., K. Mattila, M. S. Nieminen, P. H. Makela, J. K. Huttunen, and V. Valtonen. 1988. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet ii:983-986.
44. Saiman, L., B. C. Marshall, N. Mayer-Hamblett, J. L. Burns, A. L. Quittner, D. A. Cibene, S. Coquillette, A. Y. Fieberg, F. J. Accurso, and P. W. Campbell. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. JAMA 290:1749-1756.
45. Takeshita, K., I. Yamagishi, M. Harada, S. Otomo, T. Nakagawa, and Y. Mizushima. 1989. Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp. Clin. Res. 15:527-533.
46. Uriarte, S. M., R. E. Molestina, R. D. Miller, J. Bernabo, A. Farinati, K. Eiguchi, J. A. Ramirez, and J. T. Summersgill. 2002. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-α. J. Infect. Dis. 185:1631-1636.
47. Van der Auwera, P., T. Matsumoto, and M. Husson. 1988. Intraphagocytic penetration of antibiotics. J. Antimicrob. Chemother. 22:185-192.
48. Van Vlem, B., R. Vanholder, P. De Paepe, D. Vogelaers, and S. Ringoir. 1996. Immunomodulating effects of antibiotics: literature review. Infection 24:275-291.